{"id":4420,"date":"2020-03-19T16:39:56","date_gmt":"2020-03-19T13:39:56","guid":{"rendered":"http:\/\/www.alfapatent-stanadvoka.com\/?p=4420"},"modified":"2022-06-13T12:16:00","modified_gmt":"2022-06-13T09:16:00","slug":"t2428-17","status":"publish","type":"post","link":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/t2428-17\/","title":{"rendered":"19.03.2020 \/T 2428\/17 \/RE-TARGETED TOXIN CONJUGATES \/IPSEN BIOINNOVATION"},"content":{"rendered":"

EP 1 667 725<\/a>\u00a0numaral\u0131 patent \u0130nceleme Birimi taraf\u0131ndan reddedilmi\u015ftir. Ret gerek\u00e7esi yeniliktir. Temyiz incelemesine konu ana talebe ait ba\u011f\u0131ms\u0131z istemler a\u015fa\u011f\u0131da yer almaktad\u0131r:<\/p>\n

“1. A method of preparing a non-cytotoxic toxin conjugate for the inhibition or reduction of secretion from a target cell, which method comprises:<\/p>\n

(A) identifying an agonist that increases said secretion from said target cell upon binding of the agonist to a receptor on said target cell wherein said receptor undergoes endocytosis to be incorporated into an endosome within said target cell; and<\/p>\n

selecting said agonist as a targeting moiety on the basis of its specific agonist properties; and<\/p>\n

(B) preparing a non-cytotoxic protease conjugate, said conjugate comprising:<\/p>\n

(i) an agonist targeting moiety identified by step (A), wherein said agonist binds the conjugate to a receptor on said target cell;<\/p>\n

(ii) a non-cytotoxic protease or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of said target cell; and<\/p>\n

(iii) a Translocation Domain that translocates the proteases or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the target cell.”.<\/p>\n

“2. A method of preparing a non-cytotoxic toxin conjugate for the inhibition or reduction of secretion from a target cell, which method comprises:<\/p>\n

(A) identifying an agonist that increases said secretion from said target cell upon binding of the agonist to a receptor on said target cell wherein said receptor undergoes endocytosis to be incorporated into an endosome within said target cell; and<\/p>\n

selecting said agonist as a targeting moiety on the basis of its specific agonist properties; and<\/p>\n

(B) preparing a non-cytotoxic protease conjugate, said conjugate comprising:<\/p>\n

(i) an agonist targeting moiety identified by step (A), wherein said agonist binds the conjugate to a receptor on said target cell;<\/p>\n

(ii) a DNA sequence encoding a non-cytotoxic protease or a fragment thereof, which DNA sequence is expressible in the target cell and when so expressed provides a protease or protease fragment capable of cleaving a protein of the exocytic fusion apparatus of said target cell; and<\/p>\n

(iii) a Translocation Domain that translocates the DNA sequence encoding the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the target cell.”.<\/p><\/blockquote>\n

 <\/p>\n

Temyiz Kurulu\u2019nun 27.03.2019 tarihli yaz\u015fmas\u0131nda ana talebe ait istem setinin yeni olmad\u0131\u011f\u0131 g\u00f6r\u00fc\u015f\u00fc sunulmu\u015f ve 1 ile 3 numaral\u0131 terditli taleplerdeki istemlerin EPC\u00a0Md. 53(c)<\/a>\u00a0alt\u0131nda te\u015fhis ve tedavi usullerine ili\u015fkin olduklar\u0131 ifade edilmi\u015ftir. Temyiz sahibi kar\u015f\u0131 cevap sunmam\u0131\u015f ve daha sonraki yaz\u0131\u015fmas\u0131nda duru\u015fmaya kat\u0131lmayaca\u011f\u0131n\u0131 ifade etmi\u015ftir. 16 Mart 2020 i\u00e7in planlanm\u0131\u015f duru\u015fma iptal edilmi\u015ftir.<\/p>\n

Temyiz Kurulu yenilik incelemesinde \u201cHedef h\u00fccreden sekresyonun inhibisyonu veya azalt\u0131lmas\u0131 i\u00e7in sitotoksik olmayan bir toksin konjugat\u0131n\u0131n haz\u0131rlanmas\u0131\u201d olarak tan\u0131mlanm\u0131\u015f prosesin A ve B ad\u0131mlar\u0131n\u0131n bir agonist hedefleme par\u00e7as\u0131n\u0131n tan\u0131mlanmas\u0131 ad\u0131m\u0131 (A) ve konjugat\u0131n haz\u0131rlanmas\u0131 (B) ad\u0131m\u0131 \u015fklinde \u00f6nceki teknikte bilinen ad\u0131mlar olduklar\u0131n\u0131 ve prosesin amac\u0131n\u0131n tan\u0131mland\u0131\u011f\u0131 \u201cHedef h\u00fccreden sekresyonun inhibisyonu veya azalt\u0131lmas\u0131 i\u00e7in sitotoksik olmayan bir toksin konjugat\u0131n\u0131n haz\u0131rlanmas\u0131\u201d ifadesinin de istemi s\u0131n\u0131rland\u0131r\u0131c\u0131 kabul edilemeyece\u011fini ifade etmektedir. Daha a\u00e7\u0131k bir ifadeyle bilinen bir prosesin bir \u00f6zelli\u011finin daha a\u00e7\u0131k olarak ortaya konmas\u0131 veya yine bilinen bir proses s\u0131ras\u0131nda ortaya yeni \u00e7\u0131kan bir etkinin a\u00e7\u0131klanmas\u0131 prosesin yeni olmad\u0131\u011f\u0131 sonucunu de\u011fi\u015ftirmemektedir. Kurul karar\u0131nda \u015fu ifadelere yer vermi\u015ftir:<\/p>\n

\u201cThe Board observes that a manufacturing process for the preparation of a product does not become new simply by indicating or explaining a property of a product, possibly previously unknown or even unexpected in the art, or by the mere explanation of an effect\u201d<\/em><\/p>\n

Di\u011fer yandan 1 numaral\u0131 ve 3 numaral\u0131 yard\u0131mc\u0131 taleplere ait ba\u011f\u0131ms\u0131z istemlerin tan\u0131mlar\u0131 yukar\u0131daki ana talepteki \u00fcretim prosesi istemlerinden farkl\u0131 olarak\u00a0\u201cUse of a conjugate to inhibit or reducing a secretion from a target cell\u201d<\/em>, \u015feklinde tarifnamede de patolojik bir duruma kar\u015f\u0131 tedavi \u00f6zelli\u011fine sahip oldu\u011fu belirtilen bir i\u015flevi tan\u0131mlamaktad\u0131r. Ana talep ve 2. terditli talep\u00a0\u00a0istemleri yenilik eksikli\u011fi ve 1 ile 3. terditli talepler ise tedavi usulleri tan\u0131mlad\u0131klar\u0131 i\u00e7in temyiz reddedilmi\u015f ve \u0130nceleme Birimi’ne ait ret karar\u0131 onanm\u0131\u015ft\u0131r.<\/p>\n","protected":false},"excerpt":{"rendered":"

EP 1 667 725\u00a0numaral\u0131 patent \u0130nceleme Birimi taraf\u0131ndan reddedilmi\u015ftir. Ret gerek\u00e7esi yeniliktir. Temyiz incelemesine konu ana talebe ait ba\u011f\u0131ms\u0131z istemler<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[112],"tags":[],"class_list":["post-4420","post","type-post","status-publish","format-standard","hentry","category-t-kararlar"],"_links":{"self":[{"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/posts\/4420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/comments?post=4420"}],"version-history":[{"count":3,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/posts\/4420\/revisions"}],"predecessor-version":[{"id":4423,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/posts\/4420\/revisions\/4423"}],"wp:attachment":[{"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/media?parent=4420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/categories?post=4420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.alfapatent-stanadvoka.com\/tr\/wp-json\/wp\/v2\/tags?post=4420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}